47 results about "Host immunity" patented technology

The invention belongs to the technical field of medicines, and particularly discloses application of fibronectin 1 (FN1) in treatment of mycobacterial infection. The invention finds that the FN1 has new application, and the survival of mycobacteria can be inhibited when the FN1 is independently applied; in a mycobacterium infection model, after the FN1 protein is exogenously added, the number of mycobacteria in macrophages is remarkably reduced; on the contrary, after the FN1 is knocked down, the number of mycobacteria in the macrophage is obviously increased. Further mechanism research shows that the FN1 affects release of reactive oxygen species (ROS) and cytokines by regulating a PI3K / AKT signaling pathway, and further removes mycobacteria in macrophages. From the perspective of host immunity, the invention discloses a mechanism that FN1 affects ROS (reactive oxygen species) and inflammatory response by regulating a PI3K / AKT signal channel so as to inhibit mycobacteria, and a new medicine is provided for treatment of mycobacteria infection. On the basis, FN1 can be independently used or combined with first-line antituberculosis drugs, and a new means is provided for solving the problem of drug resistance in mycobacterium infection treatment.

The invention discloses a recombinant salmonella choleraesuis nuclease regulation vector as well as a construction method and application thereof. After oral administration, the recombinant salmonella choleraesuis nuclease regulatory vector rSC0140 enters host immune cells, c-di-AMP is released, a host STING pathway is activated, and a broad-spectrum antiviral effect can be achieved; the recombinant strain rSC0140 is proved to be capable of activating STING pathways in macrophages and mice, causing antiviral states of the macrophages and the mice and resisting challenge of various influenza viruses; the recombinant strain has broad-spectrum antiviral efficacy and is suitable for preventing and treating various virus diseases clinically.

Systems and methods for the detection of sepsis and treatment of patients. A sepsis detection system includes a first subsystem configured to detect the presence of an infection in a patient, a second subsystem configured to detect the presence of a dysregulated immune response in the patient, a third subsystem configured to detect organ dysfunction in the patient, a fourth subsystem configured to detect antibiotic resistance (ARB) of a pathogen in the patient, and a processing device. The first, second, third, and fourth subsystems and the processing device are communicatively coupled to each other via a network. The processing device is configured to determine the presence of sepsis in the patient based on the presence of infection, the presence of the dysregulated host response, and clinical data indicative of organ dysfunction in the patient.The subsystems utilize at least one polymerase chain reaction (PCR) procedure, Raman spectroscopy, clinical data, electronic health record (EHR) data, and antibiotic susceptibility testing (antibiogram).

This invention belongs to the field of biomedical engineering technology, providing a method for preparing modular bio-ink for cell spheres and its application in the field of myocardial repair therapy. First, a method for preparing stem cell spheres based on microarrays is described. By introducing a protein / polyphenol composite coating onto the cell spheres, a multifunctional armor is created, providing immune protection and immunomodulatory therapy against the host's immune system to reverse the hostile microenvironment and promote the healing process of infarcted myocardial tissue. Second, using microfluidic droplet control technology, gel microspheres loaded with bioactive substances are prepared from biocompatible biomaterials. These microspheres are then densely packed and coated to form cell sphere particle gels. These gels can be used for disease treatment via direct injection or bio-3D printing, showing promising application prospects.

The invention relates to the fields of molecular biology and virology, and provides a method for preparing a specific MHC haplotype-derived cell-binding virus. The method comprises the following steps: firstly, obtaining chick embryos of different haplotypes, separating CEF cells, transiently expressing exogenous fluorescent protein through electrotransfection, then carrying out virus inoculation, carrying out flow sorting to obtain a fluorescent positive cell population carrying MDV, and carrying out quantitative analysis on the cell population to obtain the specific MHC haplotype chicken Marek's Disease Virus (MDV), thereby obtaining the specific MHC haplotype chicken Marek's Disease Virus Marek's Disease Virus Marek's Disease Virus Marek's Disease Virus. And carrying out in-vitro propagation to obtain the purified MDV with a specific haplotype source. The purified virus can provide a test material for related research of haplotype on virus infection, and can be widely applied to in-vitro purification of different cell binding viruses and related research of specific MHC molecule presenting virus peptides. The method disclosed by the invention is beneficial to carrying out related research aiming at the host immune response of the virus and analyzing the hereditary basis of haplotype to MDV differential resistance, and is expected to be applied to preparation of vaccine virus.

The invention provides an optimized and far potent chimeric antigen receptor for its use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host's immune response directed against the transplant. The fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02 in a recipient patient who is negative for HLA-A*02, i.e. the patient prior to transplantation does not express HLA-A*02. The fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (Treg) causes a specific suppressor activity of the regulatory T-cells in the presence of HLA-A*02.

T lymphocytes play a key role in the immune response and their functions are intimately linked to metabolic programs. During immune responses, T cells undergo a metabolic reprogramming notably characterized by an increased aerobic glycolysis. Using a quantitative phosphoproteomic approach, the inventors have identified a new transcription factor called Foxk1 as being highly phosphorylated in T cells upon T Cell Receptor (TCR) engagement. The results also indicate that Foxk1 phosphorylation and nuclear translocation is dependent of the AKT-mTOR kinase activities. Using T-cell specific Foxk1 deficient mice (Foxk1- / -), we demonstrated that Foxk1 is required for full T cell activation. Foxk1-deficient T cells exhibited reduced proliferation and cytokine secretion following TCR stimulation. Furthermore, T cells from Foxk1- / - mice were less prone to acquire an effector like phenotype than wild-type cells when challenged in vivo. Conversely, Foxk1 overexpression in T cells enhanced their effector functions in a TCR-dependent manner. In CD8+ T cells, this effect also results into enhanced cancer cell killing capacity in vitro, and improved tumor rejection in vivo. Altogether, these results indicated that Foxk1 is a major regulator of T cell metabolism and thus, of T cell effector functions. Thus, the present invention relates to host immune cells engineered to overexpress a Foxk1 polypeptide and their use of the treatment of cancer.

This invention relates to the field of appropriate immunotherapy for activating the immune response in patients. More specifically, the present invention relates to negative anti-EPO function modulators useful as active ingredients in pharmaceutical compositions for immunomodulatory strategies in therapies (e.g., cancer immunotherapy, therapies for infectious and inflammatory diseases) or for activating the immune system, enhancing cell-based or pharmacological or vaccine-based immunotherapy, and stimulating the immune system response of patients as needed. In particular, the present invention also describes how to restore the immune response in pathological conditions such as cancer and refractory infections, for example, by enhancing and ensuring therapeutic access to immunotherapy strategies by products consisting of EPO pathway inhibitors that can function as active pharmaceutical ingredients in vaccine compositions that stimulate the immune response in cancer, infectious diseases, and inflammatory diseases and be delivered to patients, thereby eliminating "tolerogenic" stimulation.

Provided herein are methods for managing host immune responses to improve therapeutic outcomes in adeno-associated virus (AAV)-mediated gene therapy. Such methods may include administering a recombinant adeno-associated virus (rAAV) to a subject following administration of a CD19 inhibitor, e.g., an anti-CD19 antibody. The methods described herein can facilitate improved transgene expression, help overcome pre-existing NAbs, and / or permit redosing with the same or substantially similar rAAV or transgene.

The invention discloses a flavonoid compound with an effect of reducing MRSA toxicity and application of the flavonoid compound in neutralizing alpha-hemolysin, and belongs to the technical field of medicinal chemistry. The flavonoid compounds can inhibit secretion of MRSA to alpha-hemolysin (Hla), so that the infection toxicity of MRSA to a host is reduced, and meanwhile, the compounds do not inhibit growth of MRSA, so that generation of drug resistance of MRSA can be greatly reduced. Besides, the compounds can also neutralize alpha-hemolysin (Hla) and have important medical value in clinical diagnosis and treatment, on one hand, damage of MRSA to a host immune system can be reduced, and on the other hand, the compounds are used for treating diseases caused by MRSA and reducing generation of MRSA drug resistance, so that the compounds have important significance in prevention and treatment of MRSA.

The present invention relates to a dual-target double-stranded RNA for treating hepatitis B, and a pharmaceutical composition. The dual-target double-stranded RNA comprises a first double-stranded RNA and a second double-stranded RNA, wherein one of the first double-stranded RNA and the second double-stranded RNA targets the hepatitis B virus (HBV) life cycle, and the other targets a host immune target PD-L1. The double-stranded RNA can simultaneously target the dual targets of HBV and host immune PD-L1, which can inhibit HBV replication while activating human immunity, and is therefore expected to bring about a clinical functional cure.

A new antibacterial peptide of Japanese eel A1 Cath2b 143‑174 and its application, belong to the field of biotechnology. The antibacterial peptide is a Cathelicidin family antibacterial peptide of Japanese eel A1 The 143-174 amino acid fragment of Cathelicidin 2b is named as Cath2b A1 Cath2b 143‑174 , and the amino acid sequence is shown as SEQ ID NO. 3. The antibacterial peptide has high inhibition / killing activity on various aquatic pathogenic bacteria, has excellent thermal stability and salt ion tolerance, and has no obvious toxicity to host cells; it plays a bactericidal role by destroying the bacterial cell membrane, and can also attract host immune cells to enhance immunity. The antibacterial peptide can be applied in the preparation of aquatic animal bacterial disease prevention and control drugs. It can solve the problems of drug resistance and drug residue caused by the abuse of traditional antibiotics, and is convenient to prepare, has strong adaptability, and is suitable for the prevention and control of bacterial diseases of aquatic animals.

The application discloses a fermented Lactobacillus mui J0273, which is preserved in the Guangdong Microbial Culture Collection Center on March 28, 2024, and has a preservation number of GDMCC No: 64463; the fermented Lactobacillus mui J0273 provided by the application has antioxidant activity, can produce indole-3-methanol, and has good DPPH free radical clearance rate, hydroxyl radical clearance rate, high reducing power, Fe 2+ Chelating capacity, can enhance the antioxidant capacity of the host, regulate the host immune, protect the intestinal barrier, and relieve inflammation.

The present invention relates to modified T cells and methods of making and using the same. Specifically, disclosed herein are modified primary human T cells, and populations thereof, comprising a genome in which the CTLA4, PD1, TCRA, TCRB, and / or B2M genes have been edited to produce off-the-shelf universal CAR T cells from allogeneic healthy donors, the off-the-shelf universal CAR T cells can be administered to any patient while reducing or eliminating the risk of immunological rejection or graft versus host disease, and are not susceptible to T cell inhibition; and methods for allogeneic administration of the cells to reduce the likelihood that the cells will trigger a host immune response when the cells are administered to a subject in need thereof.

The invention discloses a construction method of a model for respiratory tract infection caused by inhalation of pathogenic microorganism aerosol, which comprises the following steps: inoculating respiratory tract cells to an upper chamber of a Transwell cell, culturing until a complete cell barrier is formed, and transferring the cell-loaded cell to an exposure cavity; atomizing the pathogenic microorganism suspension into aerosol, and regulating and controlling environmental parameters of the aerosol in real time; introducing the aerosol into an exposure cavity, and enabling the aerosol to be in direct contact with cells in a manner of simulating the inhalation process of the respiratory tract of a human body; and after the exposure is finished, transferring to a porous plate for continuous culture. The invention further discloses application of the model for respiratory tract infection caused by inhalation of the pathogenic microorganism aerosol. The method has the beneficial effects that the model construction process is simple and convenient, the natural infection process can be highly simulated, the method can be used for simulating a bioaerosol exposure scene after specific treatment, and the method is suitable for pathogen invasion mechanism analysis, host immune response research and efficient screening of anti-infection drugs.

The application discloses application of elvitegravir in preparation of an inhibitor of mycobacterium tuberculosis or non-tuberculous mycobacteria, and relates to the technical field of biological medicine.The application discloses, for the first time, that elvitegravir has the effect of inhibiting intracellular survival of mycobacterium tuberculosis or non-tuberculous mycobacteria at the level of macrophages, has the effect of anti-tuberculosis at the level of macrophages, and can be applied to preparation of an inhibitor of mycobacterium tuberculosis or non-tuberculous mycobacteria.The application also discloses that the anti-tuberculosis effect of elvitegravir at the level of macrophages is not the direct action of antibiotics on bacteria, but the inhibition of intracellular survival of tubercle bacillus by targeting and regulating host immune response, so that elvitegravir also has the potential of an immunomodulator, can realize the anti-tuberculosis effect by regulating the immune response of the body to tubercle bacillus infection, and is not affected by drug resistance of mycobacterium tuberculosis, and has a good treatment effect on multidrug-resistant tuberculosis.

The application discloses a combination of intestinal microbial functional markers for diagnosing allergic risk of infants and young children and a construction method and application of a model thereof. The combination of intestinal microbial functional markers for diagnosing allergic risk of infants and young children and the kit thereof can accurately and efficiently diagnose the microecological allergic risk of infants and young children of different ages. By integrating multi-dimensional characteristics such as functional gene abundance and KEGG metabolic pathway function activity level, the model can reveal the core mechanism of affecting the host immunity from the perspective of the function of the flora, thereby improving the prediction efficiency and enhancing the biological interpretability of the model. The AUC of the method reaches 0.84 on the test set, indicating that the method has good ability to distinguish allergic and non-allergic individuals. The models of different age groups all have high consistency, proving that the method is stable and reliable and can meet the accuracy requirements of clinical auxiliary decision-making.

A nanoagonist, and a preparation method and use thereof are provided, belonging to the technical field of nanoscale biomedicine. The nanoagonist is formed by self-assembly of a transformable peptide, where the transformable peptide includes a targeted antimicrobial peptide, a functionalized self-assembling peptide, an FcγR recognition peptide, and a lipase-responsive hydrophobic molecule that are coupled in sequence. The functionalized self-assembling peptide can control the FcγR recognition peptide to flip toward a surface of a target pathogen during secondary self-assembly, and the target pathogen is a pathogen targeted and bound by the targeted antimicrobial peptide. The nanoagonist combines externalization of the FcγR recognition peptide that can be guided during the secondary self-assembly with FcγR-mediated endocytosis, and a nanoagonist is developed for the first time that takes into account both pathogen clearance and host immune function repair.

The application discloses a method for constructing an animal model of chronic pulmonary infection / persistence of Acinetobacter baumannii, and belongs to the technical field of infectious disease animal model construction and microbial preparation. Compared with the acute infection and rapid clearance mode formed by directly inoculating free bacteria, the live bacterial microspheres prepared in the application can prolong the local exposure and detectable time of Acinetobacter baumannii in the lung, so that the Acinetobacter baumannii is more likely to form a low-load, long-term persistence pulmonary infection state, thereby providing a more stable experimental platform for the mechanism of chronic infection formation, host immune dynamic change and related intervention evaluation.

The application discloses a ruthenium polypyridyl complex with polybasic cyclic and quaternary ammonium salt structures and a preparation method and application thereof. The ruthenium polypyridyl complex with polybasic cyclic and quaternary ammonium salt structures comprises metal ions, is coordinated with bipyridine with different substituents and has a positive charge, can be combined with negative ions on the surface of a bacterial cell membrane, destroys the bacterial cell membrane, thereby inhibits the growth of bacteria and finally kills the bacteria. Staphylococcus aureus can produce a multi-layer biofilm embedded in a cell envelope and a slime layer, and expresses proteins with heterogeneity in the whole process, hinders the penetration of drugs and increases the chance of host immune escape, helps the bacteria resist the environment and causes persistent infection, so that inhibiting the formation of the biofilm is a key point of antibacterial medical technology research. The carbon chain structure, polybasic heterocyclic structure and quaternary ammonium salt structure are introduced into the ruthenium polypyridyl ligand, the ability of destroying the bacterial cell membrane is enhanced through the action of different groups, and the biological activity is improved.

The application discloses a construction method of a microbial-metabolite-host regulation network of summer South China calf based on Lactobacillus reuteri, and belongs to the technical field of microorganisms. The construction method comprises the following steps: collecting rumen, fecal sample and whole blood sample of the summer South China calf; obtaining microbial layer data through 16S rRNA sequencing, obtaining metabolite layer data through non-target metabolomics, and obtaining host gene / pathway layer data through whole blood transcriptomics; performing correlation analysis on multi-omics data to obtain a microbial-metabolite-host regulation correlation network. The regulation network significantly improves the growth performance of the summer South China calf, relieves diarrhea and enhances the digestive absorption function by improving the abundance of gastrointestinal beneficial bacteria, promoting the secretion of short-chain fatty acids and activating the host immune antioxidant pathway. The application realizes the precise mechanized application of probiotics by clarifying the regulation correlation among the three, and provides a mechanism-application integrated scheme for healthy breeding of calves.

The present invention features fusion proteins comprising an immunoglobulin G-degrading enzyme domain and an albumin binding domain. The albumin binding domain can bind to human serum albumin and can be useful, for example, for increasing the half-life of the immunoglobulin G-degrading enzyme domain in a subject. Uses of the fusion protein include treatment reducing a potential host immune response to an administered treatment such as those involving a viral vector, or involving a tissue or organ transplant; treating an adverse IgG immune response; and treating an autoimmune disease or disorder.

The invention provides application of a BTLA inhibitor in preparation of a medicine for preventing and / or treating chronic hepatitis B, and belongs to the technical field of biological medicine. Research finds that antagonistic B and T lymphocyte attenuation factors (BTLA) can promote removal of hepatitis B surface antigen (HBsAg), reduce the expression level of HBeAg, promote activation and proliferation of T cells and enhance host immune response, so that the purpose of preventing and / or treating chronic hepatitis B is achieved, and functional cure of chronic hepatitis B (CHB) is achieved. The invention provides more choices for medicines for clinically preventing and / or treating chronic hepatitis B.

A system for detecting infection is provided. The system includes a pathogen detection component for detecting a pathogen, a host immune response component for detecting a host immune response associated with the pathogen, and an antimicrobial resistance component for detecting an antimicrobial resistance associated with the pathogen.

The application discloses a postbiotic prepared from saliva combined lactobacillus and having the function of improving expression of host antibacterial peptide and immunoglobulin and application thereof, and belongs to the technical field of microorganisms. The saliva combined lactobacillus has the ability of regulating host immunity and improving host oral cavity anti-pathogenic bacteria infection, can significantly up-regulate expression of human oral cavity keratinocyte antibacterial peptide HBD-2 gene and protein in vitro, can significantly up-regulate expression of DEFB3 (homolog of human HBD-2) and secreted immunoglobulin SIgA in mice in vivo, and can be used for preparing a series of products for enhancing host oral cavity immunity and resisting oral cavity pathogenic bacteria infection, and has great application prospect.

The application discloses a kind of multilocular hydatid Em Preparation method of 6B protein and application thereof in preparation of anti-host inflammatory response preparation. By protein structure modeling, molecular docking technology, it is confirmed that Em 6B can be combined with host 26S proteasome key subunit with high affinity, affect the assembly of host proteasome in vivo, and then intervene the activity of NF-κB signal pathway, so as to regulate host inflammatory response. Through animal experiment, it is shown that recombinant Em 6B intervention can significantly alleviate the colon injury of inflammatory bowel disease mice, regulate the expression level of pro-inflammatory and anti-inflammatory factors, and improve the survival rate of sepsis mice, and no obvious toxic side effects are observed. The application opens up a new path for developing anti-inflammatory preparations using parasite-host immune interaction natural molecules, and provides a kind of anti-host inflammatory response biological preparation technical scheme with novel mechanism of action and good biological safety, which has good application potential in the prevention and treatment of human and livestock inflammatory diseases.

The application discloses a cell membrane modified nanocomposite as well as a preparation method and application thereof. The nanocomposite comprises, from outside to inside, a membrane structure outer layer, a piezoelectric material middle layer and a magnetostrictive material core structure, wherein the outer surface of the membrane structure contains protein molecules. Under the stimulation of an external magnetic field, the nanocomposite can regulate Th1 / Th2 balance, promote Th2 cell polarization and enhance T cell proliferation, thereby reducing T cell-mediated autoimmune reactions and maintaining host immune homeostasis, and has a wide application prospect in the treatment of arthritis.

This invention discloses a multilocular echinococcosis larva. In Preparation method of -6B protein and its application in the preparation of anti-host inflammatory agents. Through protein structure modeling and molecular docking technology, the preparation method was confirmed. In -6B can bind with high affinity to a key subunit of the host 26S proteasome, affecting the assembly of the proteasome in the host and thus interfering with the activity of the NF-κB signaling pathway, thereby regulating the host inflammatory response. Animal experiments have shown that recombinant... In -6B intervention significantly alleviated colonic damage in mice with inflammatory bowel disease, regulated the expression levels of pro-inflammatory and anti-inflammatory factors, and improved the survival rate of septic mice, with no obvious toxic side effects observed. This invention opens up a new pathway for developing anti-inflammatory agents using natural molecules that interact with the parasite's immune system, and provides a novel mechanism of action and biosafety for anti-host inflammatory biological agents, showing great potential for application in the prevention and treatment of inflammatory diseases in humans and livestock.

To provide a biocompatible membrane composite capable of providing an environment capable of mitigating or controlling a foreign body reaction.SOLUTION: The membrane composite includes a conformable layer and a vascularizing layer. A reinforcing component can optionally be included to provide support to the biocompatible membrane composite invivo and prevent distortion of the membrane composite. The relief layer may be coupled or attached to the implantable device and / or the cell system. The biocompatible membrane composite can be used as a surface layer for implantable devices or cell systems that require vascularization for function but require protection from a host immune response, such as the formation of foreign body giant cells. The biocompatible membrane composite can partially or completely cover the exterior of the implantable device or cell system. The relief layer is positioned between the implantable device or bioactive scaffold and the vascularizing layer.SELECTED DRAWING: Figure 7

The present invention provides a hyperthermia-induced gut microbiome- mediated modulation of the host immune system for the treatment of gastric / gastric MALT / Duodenum cancer; the said system uses a wild type / non-pathogenic / attenuated strain coated with iron oxide nanoparticles to specifically target the cancerous tissue by applying an external field around the gastric tissue the said iron oxide generates heat on bacteria surface and causes lysis of bacteria in the tumor microenvironment; the lysis of bacteria triggers various potent immune activator and cytokines to activate antigen-presenting cells including lymphocytes and macrophages; the said antigen presenting cell further, eliminates cancer cell from the gut microenvironment and eventually clean tumor microenvironment. Additionally, the activated lymphocytes will be antigenic memory against bacterial particles and cancer tissues. Furthermore, the said treatment system does not involve the use of any chemotherapeutic drug or radiation treatment and, thus, precludes undesirable side effects of chemotherapy as well as minimizes toxicity.